• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ABIOMED Inc.

    12/29/22 4:03:01 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care
    Get the next $ABMD alert in real time by email
    SC 13G 1 ABMD_SC13G.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    ABIOMED, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.01 PER SHARE
    (Title of Class of Securities)

    003654100
    (CUSIP Number)

    DECEMBER 21, 2022
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    003654100

    SCHEDULE 13G

    Page  
    2
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    003654100

    SCHEDULE 13G

    Page  
    3
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    003654100

    SCHEDULE 13G

    Page  
    4
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     -0- (See Item 4(a))
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     -0- (See Item 4(a))
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     -0- (See Item 4(a))
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    003654100

     SCHEDULE 13G

    Page  
    5
      of   
    10
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      ABIOMED, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    22 Cherry Hill Drive
    Danvers, Massachusetts 01923

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.01 per share ("Common Stock")
     
      (e) CUSIP Number:
    003654100
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    003654100

     SCHEDULE 13G

    Page  
    6
      of   
    10
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

       After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on December 21, 2022, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    003654100

     SCHEDULE 13G

    Page  
    7
      of   
    10

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    003654100

    SCHEDULE 13G

    Page  
    8
      of   
    10

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of December 28, 2022, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    003654100

    SCHEDULE 13G

    Page  
    9
      of   
    10
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: December 28, 2022

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    003654100

    SCHEDULE 13G

    Page  
    10
      of   
    10
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.01 per share, of ABIOMED, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: December 28, 2022

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $ABMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABMD

    DatePrice TargetRatingAnalyst
    11/2/2022$235.00 → $380.00Underweight → Equal-Weight
    Morgan Stanley
    11/2/2022$355.00 → $388.00Buy → Hold
    Deutsche Bank
    10/13/2022$300.00Buy
    Mizuho
    4/6/2022$330.00Peer Perform
    Wolfe Research
    2/4/2022$292.00 → $275.00Underweight
    Morgan Stanley
    2/4/2022$345.00 → $325.00Market Perform
    SVB Leerink
    1/7/2022$269.00 → $292.00Underweight
    Morgan Stanley
    8/6/2021$335.00 → $375.00Market Perform
    SVB Leerink
    More analyst ratings

    $ABMD
    Financials

    Live finance-specific insights

    See more
    • Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

      ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa

      11/1/22 7:00:00 AM ET
      $ABMD
      $JNJ
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Johnson & Johnson to Acquire Abiomed

      Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil

      11/1/22 6:30:00 AM ET
      $ABMD
      $JNJ
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

      Abiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Tuesday, November 1, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/493387843 or dial (844) 200-6205; the international number is (929) 526-1599 access code 367357. A replay of this conference call will be available until Tuesday, November 8, 2022. The repla

      10/13/22 7:00:00 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

      Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

      7/12/23 9:00:00 AM ET
      $STIM
      $ABMD
      Medical/Dental Instruments
      Health Care
    • FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

      Abiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI). This press release features multimedia. View the full release here: htt

      12/21/22 9:00:00 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400

      NEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector December 22, 2022 S&P 500 Addition Steel Dynamics STLD Materials S&P 500 Deletion

      12/19/22 6:35:00 PM ET
      $ABMD
      $JNJ
      $SMCI
      $SPGI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Manufacturing

    $ABMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)

      SC 13G/A - ABIOMED INC (0000815094) (Subject)

      1/6/23 6:39:54 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by ABIOMED Inc.

      SC 13G - ABIOMED INC (0000815094) (Subject)

      12/29/22 4:03:01 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)

      SC 13G/A - ABIOMED INC (0000815094) (Subject)

      2/9/22 3:16:00 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abiomed upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Abiomed from Underweight to Equal-Weight and set a new price target of $380.00 from $235.00 previously

      11/2/22 9:11:07 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Abiomed downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Abiomed from Buy to Hold and set a new price target of $388.00 from $355.00 previously

      11/2/22 6:09:28 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Abiomed with a new price target

      Mizuho initiated coverage of Abiomed with a rating of Buy and set a new price target of $300.00

      10/13/22 7:17:59 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    SEC Filings

    See more
    • SEC Form 15-12G filed by ABIOMED Inc.

      15-12G - ABIOMED INC (0000815094) (Filer)

      1/3/23 8:30:58 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by ABIOMED Inc.

      S-8 POS - ABIOMED INC (0000815094) (Filer)

      12/22/22 4:46:31 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by ABIOMED Inc.

      S-8 POS - ABIOMED INC (0000815094) (Filer)

      12/22/22 4:46:02 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

      Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

      7/12/23 9:00:00 AM ET
      $STIM
      $ABMD
      Medical/Dental Instruments
      Health Care
    • MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

      Succeeds Derek Herrera after two-year term Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies. This announcement is being made today during the Plenary Luncheon at AdvaMed's MedTech Conference 2022, which is taking place through Oct. 26 at the Boston Convention and Exhibition Center. A U.S. Army combat Veteran, Sutherland succeeds Derek Herrera and will assume the role on January 1, 2023. This press release features multimedia. View the full release here: https

      10/24/22 12:00:00 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Dr. Paula A. Johnson Joins Abiomed Board of Directors

      Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005332/en/Dr. Paula A. Johnson joins the Abiomed Board of Directors (Photo: Business Wire) "Dr. Johnson is known internationally as a leading expert in healthcare, medical research and health policy, especially for her work advancing the health of women," said Michae

      4/28/21 8:03:00 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sutter Martin P returned 123,370 shares to the company, closing all direct ownership in the company

      4 - ABIOMED INC (0000815094) (Issuer)

      12/27/22 8:47:48 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Puhy Dorothy E returned 14,590 shares to the company, closing all direct ownership in the company

      4 - ABIOMED INC (0000815094) (Issuer)

      12/27/22 8:44:35 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Trapp Todd A returned 14,166 shares to the company, closing all direct ownership in the company

      4 - ABIOMED INC (0000815094) (Issuer)

      12/27/22 8:41:11 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care